Lake Street downgraded Tandem Diabetes (TNDM) to Hold from Buy with a price target of $12, down from $75, as a new analyst assumed coverage. While the analyst appreciates “the valuation is compelling” and thinks the company should probably demand a higher multiple, shares may be range-bound until faster U.S. growth, competitive share-taking and gross margin improvement to support AEBITDA profitability are seen.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes price target lowered to $51 from $53 at Barclays
- Positive Outlook for Tandem Diabetes Care: Buy Rating Reaffirmed Amid Growth Catalysts and Strategic Opportunities
- Tandem Diabetes Care’s Earnings Call Highlights Growth and Challenges
- Tandem Diabetes Care Gains FDA Clearance for SteadiSet
- Tandem Diabetes price target lowered to $20 from $27 at TD Cowen